Movement Disorder Trials
As part of an academic medical center, the Division of Movement Disorders at Northwestern University Feinberg School of Medicine aims to improve human health through scientific research. Clinical trials test or study drugs, surgical procedures, medical devices or interventions with human subjects. They look to determine their safety and effectiveness in relation to treating specific diseases. Clinical trials are part of clinical research and are at the heart of all medical advances.
The following searchable list includes all the movement disorder clinical trials currently looking for participants.
| Trials |
|---|
Movement Disorders BiorepositoryThis is a registry aimed to collect biologic and clinical information, such as blood and tissue samples, and family and medical histories from patients diagnosed with a movement disorder. The purpose of studying materials from the registry is to identify factors that either cause these neurologic conditions or increase one’… This is a registry aimed to collect biologic and clinical information, such as blood and tissue samples, and family and medical histories from patients diagnosed with a movement disorder. The purpose of studying materials from the registry is to identify factors that either cause these neurologic conditions or increase one’s risk for developing them. Samples collected for this biorepository include a blood sample (or a saliva sample) and a skin biopsy. Participants may choose to donate one or both samples. Copy Study URL to Clipboard Copy |
Enroll-HD: A Prospective Registry Study in a Global Huntington’s Disease CohortThe purpose of this research study is to collect clinical information about patients and their health. We will also collect biological samples, such as blood and DNA (the genetic material in your blood). Researchers will use this information and samples to learn more about HD and to try to find … The purpose of this research study is to collect clinical information about patients and their health. We will also collect biological samples, such as blood and DNA (the genetic material in your blood). Researchers will use this information and samples to learn more about HD and to try to find new treatments for the disease. People from many countries contribute to Enroll-HD. Eligibility CriteriaIndividuals 18 yrs or older affected by Huntington's Disease (HD) or from a HD family or are a "community control" (a person who does not carry the HD genetic mutation that causes Huntington's disease and is not part of an HD family, but would like to participate in the study). Research visits are conducted yearly and will consists of a collection of medical and family history and biological samples. Location(s)
IRB number STU00203021 Copy Study URL to Clipboard Copy |
Clinical Research Consortium for the Study of Cerebellar Ataxia (CRC-SCA) to Study Natural History and Genetic Modifiers in Spinocerebellar Ataxia (SCA)The purpose of this study is to collect natural history data among ataxia patients in a cohort of SCA 1, 2, 3, 6 patients using clinic-based neurological rating scales and performance measures. Another study goal is to identify new measures of ataxia, cognition, and neurobehavior in comparison to traditional … The purpose of this study is to collect natural history data among ataxia patients in a cohort of SCA 1, 2, 3, 6 patients using clinic-based neurological rating scales and performance measures. Another study goal is to identify new measures of ataxia, cognition, and neurobehavior in comparison to traditional clinician rating methods. The gene analysis is expected to establish a relationship, if any, between age at onset of disease and disease progression rates. Eligibility Criteria• Age 18 and older • Presence of symptoms and signs of ataxia • Molecular diagnosis of SCA 1, 2, 3, 6 either in the participant or an affected family member • Willingness to participate in the study and ability to give informed consent. Location(s)
Copy Study URL to Clipboard Copy |
A Phase 1 Single- and Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB094 Administered Intrathecally to Adults With Parkinson’s Disease (Protocol# 254PD101)The purpose of study is to determine whether BIIB094 may improve PD symptoms in subjects with or without changes in the LRRK2 gene. The study medication will be given as an injection into your back near the spinal cord. This iscalled an “intrathecal” injection.… The purpose of study is to determine whether BIIB094 may improve PD symptoms in subjects with or without changes in the LRRK2 gene. The study medication will be given as an injection into your back near the spinal cord. This iscalled an “intrathecal” injection. Eligibility Criteria 2. Diagnosis of PD w/in 7yrs without motor fluctuationsor dyskinesia. 3. Not on any medication for PD or on stable therapy for 8weeks prior to screening. Location(s)
Keywords Parkinson's disease Copy Study URL to Clipboard Copy |
Study in Parkinson Disease of Exercise Phase 3 Clinical Trial: SPARX3This study is a Phase 3 multi-site, randomized, evaluator-masked, study of endurance treadmill exercise on changes in the MDS-UPDRS Part III score at 12 months. Subjects will be randomly assigned to 2 endurance exercise groups: 1) moderate intensity exercise: 60-65% HRmax or 2) high intensity exercise: … This study is a Phase 3 multi-site, randomized, evaluator-masked, study of endurance treadmill exercise on changes in the MDS-UPDRS Part III score at 12 months. Subjects will be randomly assigned to 2 endurance exercise groups: 1) moderate intensity exercise: 60-65% HRmax or 2) high intensity exercise: 80-85% HRmax. The endurance exercise will be 4 days per week for approximately 30 minutes per session for 18 months. Eligibility Criteria -Diagnosis of Parkinson's disease for less than 3 years -Cannot be treated with any PD medication Copy Study URL to Clipboard Copy |
A Phase 1/2a Open-Label Ascending Dose Study to Evaluate the Safety and Effects of LY3884961 in Patients with Parkinson’s Disease with at Least One GBA1 Mutation (PROPEL, Protocol #: J3Z-MC-OJAA previously called PRV-PD101)PR001A is an investigational gene therapy product that is being developed for the treatment of PD in patients with GBA1 mutations. The purpose of this study is to find out what effects PR001A has on Parkinson’s disease patients. Participants will be assigned to receive one dose of PR001A by … PR001A is an investigational gene therapy product that is being developed for the treatment of PD in patients with GBA1 mutations. The purpose of this study is to find out what effects PR001A has on Parkinson’s disease patients. Participants will be assigned to receive one dose of PR001A by injection into the cisterna magna (a large space at the base of the brain). Eligibility Criteria 1. 40-75 years of age. 2. Diagnosis of PD with H&Y 3-4. 3. On stable PD therapy for 8 weeks prior to baseline. 4. At least 1 GBA gene mutation. Location(s)
Keywords Parkinson's disease Copy Study URL to Clipboard Copy |
The Parkinson’s Progression Markers Initiative (PPMI) 2.0 Clinical - Establishing a Deeply Phenotyped PD CohortThe purpose of this study is to obtaininformation from people with and without Parkinson disease (PD) so thatresearchers may better understand how Parkinson disease progresses, in order toinform better treatments. Participants will have a neurological examination, a brain scan, provide blood samples and complete some questionnaires.… The purpose of this study is to obtaininformation from people with and without Parkinson disease (PD) so thatresearchers may better understand how Parkinson disease progresses, in order toinform better treatments. Participants will have a neurological examination, a brain scan, provide blood samples and complete some questionnaires. Copy Study URL to Clipboard Copy |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Arm, Multicenter Study Evaluating the Efficacy and Safety of Pridopidine in Patients with Early Stage of Huntington DiseaseThe purpose of this study is to evaluate the safety and effectiveness of the study drug, pridopidine,on everyday functioning and daily activities, as well as movement and behaviorin participants with early stage Huntington Disease (HD)… The purpose of this study is to evaluate the safety and effectiveness of the study drug, pridopidine,on everyday functioning and daily activities, as well as movement and behaviorin participants with early stage Huntington Disease (HD) Eligibility Criteria 1. >25yrs of age. 2. Diagnosis of HD with CAG repeat > 36 Location(s)
Keywords Huntington's Disease Copy Study URL to Clipboard Copy |
A Double-Blind Placebo-Controlled, Randomized 18-Month Phase 2A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinectics of Oral UCB0599 in Study Participants with Early Parkinson’s DiseaseThis study is for people with early-stage Parkinson's disease. The objective of this study is to find out whether UCB0599, an investigational medication, can slow down the progression of PD. This study also tests whether UCB0599 is safe and tolerable. This study is placebo-controlled and will last … This study is for people with early-stage Parkinson's disease. The objective of this study is to find out whether UCB0599, an investigational medication, can slow down the progression of PD. This study also tests whether UCB0599 is safe and tolerable. This study is placebo-controlled and will last about 21 months. If you join the study, you will have regular scheduled appointments with the study staff and will have medical procedures and tests during these visits, like imaging studies, body function tests, and questionnaires. Eligibility Criteria You might be a candidate for this study if:
There are additional eligibility criteria that will be discussed with you. Location(s)
Keywords Parkinson's disease Copy Study URL to Clipboard Copy |
A Phase 3 Clinical Study of UX701 AAV-mediated Gene Therapy for the Treatment of Wilson DiseaseThe purpose of this research study is to assess if an investigational product (study drug), called UX701, is an effective and safe treatment for adults aged 18 years or older with Wilson disease. Eligibility Criteria 1.Individuals ≥ 18 years of age at the time of informed consent. 2. Confirmed diagnosis of Wilson disease. 3. Stable Wilson Disease with no medication or dose changes for at least 6 months at Screening. 4. Ongoing restriction of high copper containing foods for at least 6 months at Screening and continued through study participation. Copy Study URL to Clipboard Copy |
Web-based Automated Imaging Differentiation of ParkinsonismThis study is for people who have Parkinson's disease (PD), multiple system atrophy (MSA), or progressive supranuclear palsy (PSP). The objective of this study is to find out whether an advanced imaging study can distinguish people with PD, MSA, or PSP from one another. The imaging study uses a … This study is for people who have Parkinson's disease (PD), multiple system atrophy (MSA), or progressive supranuclear palsy (PSP). The objective of this study is to find out whether an advanced imaging study can distinguish people with PD, MSA, or PSP from one another. The imaging study uses a brain MRI (without dye or contrast) along with a web-based automated software tool that analyzes the MRI data automatically. The study requires two visits, one at the start and one 12-18 months later. The MRI is only performed at the first visit. At each visit, there are assessments of movement and thinking, along with several questionnaires. Eligibility Criteria
Location(s)
IRB number STU00214779 Copy Study URL to Clipboard Copy |
A PHASE IIB, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVENOUS PRASINEZUMAB IN PARTICIPANTS WITH EARLY PARKINSON'S DISEASEThis is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson's Disease (PD) who are on stable symptomatic PD medication.… This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson's Disease (PD) who are on stable symptomatic PD medication. Eligibility Criteria • Diagnosis of PD for at least 6 months to maximum 3 years at screening and between 50-85 years of age • On symptomatic PD medication for at least 6 months, with a stable dose for 3 months prior to baseline • No dyskinesisa or motor fluctuations (i.e. MDS-UPDRS Part IV = 0) Copy Study URL to Clipboard Copy |
A novel measurement concept to objectively quantify severity of vocal and speech related symptoms associated with Parkinson’s Disease.The purpose of this study is to determine whether smartphone app-based digital speech assessments can provide speech data that is ofsufficient quality and compliance to support analysis and are usable and relevant to PD and prodromal PD patients with varying ranges of speech symptom severity.… The purpose of this study is to determine whether smartphone app-based digital speech assessments can provide speech data that is of sufficient quality and compliance to support analysis and are usable and relevant to PD and prodromal PD patients with varying ranges of speech symptom severity. Eligibility Criteria IRB number STU00216902 Copy Study URL to Clipboard Copy |
Multi-center, Noninterventional Study Evaluating Variability, Reliability, and Compliance for the Parkinson’s Disease DiaryThe primary objective of the study is to assess the impact of the frequency of assessments on the variability over time, reliability, and compliance for the PD diary in patients with PD in whom medications do not provide adequate control of symptoms.… The primary objective of the study is to assess the impact of the frequency of assessments on the variability over time, reliability, and compliance for the PD diary in patients with PD in whom medications do not provide adequate control of symptoms. Eligibility Criteria 1.≥39 to ≤70 years of age at signing of informed consent 2. Diagnosis of clinically established PD 3. Marked levodopa responsiveness at screening per investigator’s judgment 4. A minimum of 3 years and a maximum of 18 years from time of PD diagnosis to the date of screening 5. Receiving optimized and stable PD medical therapy for ≥1 month prior to screening or demonstrated intolerance to PD medications per investigator’s judgment in agreement with the medical monitor 6. ≥3 hours of average daily OFF-time assessed within 3 months of screening by PD diary or per investigator’s judgment Location(s)
IRB number STU00217962 Copy Study URL to Clipboard Copy |
A STUDY TO EVALUATE THE SAFETY, BIOMARKERS, AND EFFICACY OF TOMINERSEN IN INDIVIDUALS WITH PRODROMAL AND EARLY MANIFEST HUNTINGTON’S DISEASEThe purpose of this study is to evaluate the safety of tominersen compared with placebo. The study drug will be administered via intrathecal injection. Eligibility Criteria Copy Study URL to Clipboard Copy |
A Multi-Center, Controlled Study to Evaluate Use of CereGate Therapy to Reduce Freezing of Gait in Participants Diagnosed with Parkinson’s DiseaseThe primary objective of this study is to determine whether adjunctive use of Ceregate therapy reduces freezing of gait (FOG) in participants diagnosed with Parkinson's disease.… The primary objective of this study is to determine whether adjunctive use of Ceregate therapy reduces freezing of gait (FOG) in participants diagnosed with Parkinson's disease. Eligibility Criteria Participants diagnosed with Parkinson’s Disease (PD) and previously implanted with a subthalamic nucleus deep brain stimulation (STN-DBS) System. Copy Study URL to Clipboard Copy |
A 17-week Study of the Efficacy and Safety of Suvecaltamide in the Treatment of Moderate to Severe Residual Tremor in Participants with Parkinson’s DiseaseThe purpose of this study is to evaluate the efficacy of suvecaltamide administered once daily for 17 weeks to improve functional and performance-based impairment due to tremor.… The purpose of this study is to evaluate the efficacy of suvecaltamide administered once daily for 17 weeks to improve functional and performance-based impairment due to tremor. Eligibility Criteria Copy Study URL to Clipboard Copy |
Evoked Compound Action Potentials for Parkinson’s Disease (eCAP-PD) Study: A prospective, multicenter, single-arm feasibility study examining ECAP-controlled, closed-loop spinal cord stimulation for Parkinson’s DiseaseThe purpose of this study is to evaluate the safety and initial efficacy of ECAP-controlled closed-loop spinal cord stimulation (SCS) to treat patients with Parkinson’s Disease symptoms.… The purpose of this study is to evaluate the safety and initial efficacy of ECAP-controlled closed-loop spinal cord stimulation (SCS) to treat patients with Parkinson’s Disease symptoms. Eligibility Criteria Subject must have moderate/severe freezing of gait and/or tremor considered as a significant source of impairment in the management of their Parkinson's disease. Copy Study URL to Clipboard Copy |